What tests are used to evaluate a mixed germ cell tumor?

Diagnostic Testing for Mixed Germ Cell Tumors

For mixed germ cell tumors, the essential diagnostic tests include histopathology from inguinal orchiectomy, serum tumor markers (AFP, β-hCG, and LDH) measured before and after orchiectomy, and CT imaging of chest and abdomen for staging. 1, 2

Core Diagnostic Approach

Histopathological Diagnosis

• Inguinal orchiectomy with histological examination is the gold standard for diagnosis and should be performed in all patients with suspected testicular germ cell tumors 1
• For patients presenting with retroperitoneal or mediastinal primary tumors, biopsy (trucut or mediastinoscopy) is required 1
• In urgent cases with extensive metastases or anterior mediastinal masses, diagnosis may be established by clinical picture combined with elevated tumor markers, allowing immediate chemotherapy initiation 1
• Core biopsies present significant diagnostic challenges, with crush artifact (83%) and necrosis (54%) frequently obscuring morphology 3

Serum Tumor Markers (Critical for Staging and Monitoring)

Three markers must be measured:

• α-fetoprotein (AFP): Elevated in 60-80% of nonseminomatous germ cell tumors; seminoma cells do not produce AFP 2, 4
• β-human chorionic gonadotropin (β-hCG): Can be elevated in both seminomas and nonseminomas 2
• Lactate dehydrogenase (LDH): Serves as a tumor mass marker and prognostic indicator 2

Timing of marker measurement:

• Before orchiectomy (essential for establishing baseline and interpreting post-operative levels) 2
• After orchiectomy (to assess for residual disease) 2
• Before each chemotherapy cycle for nonseminomas 2
• Periodically during surveillance to monitor for relapse 2

Imaging Studies

Required imaging for all patients:

• CT scan of chest and abdomen for staging and detection of metastases 1
• Chest X-ray 1
• MRI (or CT if MRI unavailable) of the brain in poor prognosis patients 1
• Bone scan may be needed in advanced metastatic disease, though uncommon in nonseminomatous tumors with limited metastases 1

For primary testicular evaluation:

• Ultrasonography and Doppler ultrasonography are the primary modalities for evaluating testicular masses 5
• MRI of the scrotum provides additional soft tissue contrast discrimination when needed 5, 6

Risk Stratification Based on Markers

The International Germ Cell Consensus Classification uses marker levels for prognosis: 1

• Good prognosis: AFP <1000 ng/mL AND β-hCG <5000 IU/L AND LDH <1.5× upper limit of normal (ULN), with non-mediastinal primary and no non-pulmonary visceral metastases 1
• Intermediate prognosis: AFP 1000-10,000 ng/mL OR β-hCG 5000-50,000 IU/L OR LDH 1.5-10× ULN, with non-mediastinal primary and no non-pulmonary visceral metastases 1
• Poor prognosis: AFP >10,000 ng/mL OR β-hCG >50,000 IU/L OR LDH >10× ULN OR mediastinal primary OR non-pulmonary visceral metastases 1

Additional Laboratory Tests

Baseline laboratory evaluation includes: 1

• Full blood count
• Urea, creatinine, and electrolytes
• Liver function tests

Immunohistochemical Markers

For challenging histopathological cases:

• OCT3/4: Crucial for diagnosing seminomas 3
• CD30: Essential for identifying embryonal carcinoma components 3
• SALL4: Useful for confirming germ cell origin 7, 3
• Placental-like alkaline phosphatase (PLAP), NANOG, AP-2γ, and LIN28: Expressed in most germ cell tumors except teratomas 8

Important Caveats

False-positive marker results can occur: 2

• AFP: Benign liver disease, hepatitis, or constitutively elevated AFP (chronically mild elevations 15-30 ng/mL) 2
• β-hCG: Pituitary production due to hypogonadism after orchiectomy, heterophilic antibodies, or tumor lysis during first week of chemotherapy 2
• LDH: Highly nonspecific—elevated by strenuous exercise, liver disease, myocardial infarction, hemolysis, and many other conditions 2

Cytokeratin expression (CAM 5.2, AE1/3) occurs in 51% of metastatic germ cell tumor biopsies and can confound diagnosis, often leading to misclassification as non-germ cell malignancies 3

Emerging Diagnostic Tools

MicroRNA-based blood tests (miR-371-3 and miR-367 clusters) are under development and may provide greater sensitivity than classical markers in some patients, though not yet standard of care 8, 4

Fluorescence in situ hybridization (FISH) for isochromosome 12p can provide additional diagnostic support in cases with atypical histology 3

What NOT to Do

• Do not use tumor markers to screen for germ cell tumors in asymptomatic individuals 2
• Do not use marker results alone to decide whether orchiectomy is indicated 2
• Do not use markers to select treatment for cancer of unknown primary 2